Salarius Pharmaceuticals Stock Today

SLRX Stock  USD 0.50  0.01  2.04%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 81

 
High
 
Low
Very High
Salarius Pharmaceuticals is trading at 0.5 as of the 17th of April 2024; that is 2.04 percent up since the beginning of the trading day. The stock's open price was 0.49. Salarius Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Salarius Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 18th of March 2024 and ending today, the 17th of April 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
29th of January 2015
Category
Healthcare
Classification
Health Care
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company has 4.31 M outstanding shares of which 268.9 K shares are at this time shorted by private and institutional investors with about 1.0 trading days to cover. More on Salarius Pharmaceuticals

Moving together with Salarius Stock

  0.64JNJ Johnson Johnson Financial Report 18th of July 2024 PairCorr

Moving against Salarius Stock

  0.45MRK Merck Company Report 25th of April 2024 PairCorr

Salarius Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Salarius Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Salarius Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
President CEODavid Arthur
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Salarius Pharmaceuticals report their recommendations after researching Salarius Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Salarius Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Salarius Pharmaceuticals. The Salarius consensus assessment is calculated by taking the average forecast from all of the analysts covering Salarius Pharmaceuticals.
Financial Strength
Based on the key indicators related to Salarius Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Salarius Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Salarius Pharmaceuticals is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.03850.0406
Notably Down
Slightly volatile
Gross Profit Margin0.590.89
Way Down
Slightly volatile
Total Current Liabilities2.3 M1.3 M
Way Up
Slightly volatile
Total Assets6.3 M6.6 M
Notably Down
Slightly volatile
Total Current Assets6.2 M6.5 M
Notably Down
Slightly volatile
Salarius Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Salarius Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Salarius Pharmaceuticals' financial leverage. It provides some insight into what part of Salarius Pharmaceuticals' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Salarius Pharmaceuticals' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Salarius Pharmaceuticals deploys its capital and how much of that capital is borrowed.
Liquidity
Salarius Pharmaceuticals cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 289.64 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Salarius Pharmaceuticals has a current ratio of 8.14, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Salarius Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Salarius Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Salarius Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Salarius to invest in growth at high rates of return. When we think about Salarius Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Other Non Cash Items

1.31 Million
Salarius Pharmaceuticals (SLRX) is traded on NASDAQ Exchange in USA. It is located in 2450 Holcombe Boulevard, Houston, TX, United States, 77021 and employs 2 people. Salarius Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.03 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Salarius Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Salarius Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Salarius Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 4.31 M outstanding shares of which 268.9 K shares are at this time shorted by private and institutional investors with about 1.0 trading days to cover. Salarius Pharmaceuticals currently holds about 22.65 M in cash with (12.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Salarius Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
Salarius Pharmaceuticals has 6.73 % of its outstanding shares held by insiders and 6.0 % owned by institutional holders.
Check Salarius Ownership Details

Salarius Stock Price Odds Analysis

Based on a normal probability distribution, the odds of Salarius Pharmaceuticals jumping above the current price in 90 days from now is about 86.94%. The Salarius Pharmaceuticals probability density function shows the probability of Salarius Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Salarius Pharmaceuticals has a beta of 0.413. This usually implies as returns on the market go up, Salarius Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Salarius Pharmaceuticals will be expected to be much smaller as well. Additionally, salarius Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
  Odds Below 0.5HorizonTargetOdds Above 0.5
12.99%90 days
 0.50 
86.94%
Based on a normal probability distribution, the odds of Salarius Pharmaceuticals to move above the current price in 90 days from now is about 86.94 (This Salarius Pharmaceuticals probability density function shows the probability of Salarius Stock to fall within a particular range of prices over 90 days) .

Salarius Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Salarius Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Salarius Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Salarius Pharmaceuticals' value.
InstituionRecorded OnShares
Blackrock Inc2023-12-31
47.0
Fmr Inc2023-12-31
33.0
Wells Fargo & Co2023-12-31
30.0
Bank Of America Corp2023-12-31
16.0
Jpmorgan Chase & Co2023-09-30
0.0
Armistice Capital, Llc2023-12-31
88 K
Horizon Asset Management Inc/ny2023-12-31
31.1 K
Susquehanna International Group, Llp2023-12-31
30.5 K
Renaissance Technologies Corp2023-12-31
26.4 K
Geode Capital Management, Llc2023-12-31
24.8 K
Vanguard Group Inc2023-12-31
14.6 K
View Salarius Pharmaceuticals Diagnostics

Salarius Pharmaceuticals Historical Income Statement

Salarius Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Salarius's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Salarius Pharmaceuticals revenue and expense. Salarius Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Salarius Pharmaceuticals' Interest Income is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 8.8 M in 2024, whereas Depreciation And Amortization is likely to drop 9,548 in 2024. View More Fundamentals

Salarius Stock Against Markets

Picking the right benchmark for Salarius Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Salarius Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Salarius Pharmaceuticals is critical whether you are bullish or bearish towards Salarius Pharmaceuticals at a given time. Please also check how Salarius Pharmaceuticals' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Salarius Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Theme Ratings Now

   

Theme Ratings

Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Salarius Pharmaceuticals Corporate Directors

Salarius Pharmaceuticals corporate directors refer to members of a Salarius Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Salarius Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Salarius Pharmaceuticals' board members must vote for the resolution. The Salarius Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Marc KozinNon-Executive Independent DirectorProfile
Michelle StacyDirectorProfile
Roger TungDirectorProfile
Stuart RandleNon-Executive Independent DirectorProfile

How to buy Salarius Stock?

Before investing in Salarius Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Salarius Pharmaceuticals. To buy Salarius Pharmaceuticals stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Salarius Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Salarius Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Salarius Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Salarius Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Salarius Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Salarius Stock please use our How to Invest in Salarius Pharmaceuticals guide.

Already Invested in Salarius Pharmaceuticals?

The danger of trading Salarius Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Salarius Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Salarius Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Salarius Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Salarius Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Salarius Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Salarius Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Salarius Pharmaceuticals Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Salarius Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Salarius Stock please use our How to Invest in Salarius Pharmaceuticals guide.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for Salarius Stock analysis

When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Stocks Directory
Find actively traded stocks across global markets
Is Salarius Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Salarius Pharmaceuticals. If investors know Salarius will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Salarius Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.84)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.76)
Return On Equity
(1.60)
The market value of Salarius Pharmaceuticals is measured differently than its book value, which is the value of Salarius that is recorded on the company's balance sheet. Investors also form their own opinion of Salarius Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Salarius Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Salarius Pharmaceuticals' market value can be influenced by many factors that don't directly affect Salarius Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Salarius Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Salarius Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Salarius Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.